Drugs / EO9
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT01475266 | Nov 2011 → Apr 2013 | urinary bladder cancer | Nippon Kayaku Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EO9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01475266 ↗ |
| Known as | Apaziquone | “EO9 (Apaziquone)” NCT01475266 ↗ |
| Route | Other | “Intravesical instillation” NCT01475266 ↗ |